Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease

NCT ID: NCT04881409

Last Updated: 2022-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

720 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-06

Study Completion Date

2024-10-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ELVIS study compares the nasal high-flow to non-invasive ventilation in treatment of acute acidotic hypercapnic exacerbation of chronic obstructive pulmonary disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ELVIS study is a prospective, randomized, multi-centre open label trial following a non-inferiority design to compare the nasal high-flow (NHF) to non-invasive ventilation (NIV) in treatment of acute acidotic hypercapnic exacerbation of chronic obstructive pulmonary disease. Accoring to the randomization the patient is treated with NHF or NIV until discharge. A change of device is possible, if switch criteria are fulfiled OR need for intubation criteria are met before 72h (timepoint for primary endpoint).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Exacerbation Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomization to NHF or NIV
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nasal high-flow

Patient with AECOPD is treated with NHF.

Group Type EXPERIMENTAL

Respiratory support with nasal high-flow (NHF)

Intervention Type DEVICE

Patient with AECOPD is treated with NHF.

non-invasive ventilation

Patient with AECOPD is treated with NIV

Group Type ACTIVE_COMPARATOR

Respiratory support with non-invasive ventilation (NIV)

Intervention Type DEVICE

Patient with AECOPD is treated with NIV.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Respiratory support with nasal high-flow (NHF)

Patient with AECOPD is treated with NHF.

Intervention Type DEVICE

Respiratory support with non-invasive ventilation (NIV)

Patient with AECOPD is treated with NIV.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. acute hypercapnic exacerbation of chronic obstructive pulmonary disease with pH \< 7.35
2. pCO2 \> 45mmHg
3. age ≥ 18 years
4. written informed consent

Exclusion Criteria

1. immediate need for intubation (acc. to intubation criteria in this protocol)
2. pH \< 7.15
3. BMI ≥ 35 kg/m²
4. established home-NIV or home-CPAP
5. end-stage disease with DNI/DNR order
6. diseases that could influence the primary endpoint: e.g. acute heart infarction, cardiogenic lung edema, acute and massive lung embolism (hypertensive), chronic dialysis with metabolic acidosis, unstable rib fracture influencing ventilation, injury to the face prohibiting use of a face mask
7. acute disease that precludes participation in the trial
8. tracheotomized patients
9. psychological/mental or other inabilities to supply required informed consent
10. participation in other interventional trials
11. suspected lack of compliance
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Leipzig

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hubert Wirtz

Head of Pneumology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

München-Klinik Bogenhausen

München, Bavaria, Germany

Site Status RECRUITING

Klinikum Emden

Emden, Lower Saxony, Germany

Site Status RECRUITING

Lungenklinik Hemer

Hemer, North Rhine-Westphalia, Germany

Site Status RECRUITING

University Hospital Leipzig

Leipzig, Saxony, Germany

Site Status RECRUITING

Sana Kliniken Ostholstein

Oldenburg in Holstein, Schleswig-Holstein, Germany

Site Status RECRUITING

Evangelische Lungenklinik

Berlin, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hubert Wirtz

Role: CONTACT

00493419712601

Nicole Köppe-Bauernfeind

Role: CONTACT

00493419716266

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christoph Dodt, Prof.

Role: primary

0049 899270707549

Jens Bräunlich, PD Dr.

Role: primary

00494921981598

Michael Westhoff, Dr.

Role: primary

004923729082201

Hubert Wirtz, Prof.

Role: primary

00493419712600

Iris Koper, Dr.

Role: primary

00494361513140

Christian Grohé, Prof.

Role: primary

004930 94802112

References

Explore related publications, articles, or registry entries linked to this study.

Braunlich J, Koppe-Bauernfeind N, Petroff D, Franke A, Wirtz H. Nasal high-flow compared to non-invasive ventilation in treatment of acute acidotic hypercapnic exacerbation of chronic obstructive pulmonary disease-protocol for a randomized controlled noninferiority trial (ELVIS). Trials. 2022 Jan 10;23(1):28. doi: 10.1186/s13063-021-05978-z.

Reference Type DERIVED
PMID: 35012620 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ELVIS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nasal High-Flow in COPD
NCT03564236 RECRUITING NA